Abstract:The use of existing mouse models in cancer research is of utmost importance as they aim to explore the casual link between candidate cancer genes and carcinogenesis as well as to provide models to develop and test new therapies. However, faster progress in translating mouse cancer model research into the clinic has been hampered due to the limitations of these models to better reflect the complexities of human tumors. Traditionally, immunocompetent and immunodeficient mice with syngeneic and xenografted tumors transplanted subcutaneously or orthotopically have been used. These models are still being widely employed for many different types of studies, in part due to their widespread availability and low cost. Other types of mouse models used in cancer research comprise transgenic mice in which oncogenes can be constitutively or conditionally expressed and tumor-suppressor genes silenced using conventional methods, such as retroviral infection, microinjection of DNA constructs, and the so-called "gene-targeted transgene" approach. These traditional transgenic models have been very important in studies of carcinogenesis and tumor pathogenesis, as well as in studies evaluating the development of resistance to therapy. Recently, the clustered regularly interspaced short palindromic repeats (CRISPR)-based genome editing approach has revolutionized the field of mouse cancer models and has had a profound and rapid impact on the development of more effective systems to study human cancers. The CRISPR/Cas9-based transgenic models have the capacity to engineer a wide spectrum of mutations found in human cancers and provide solutions to problems that were previously unsolvable. Recently, humanized mouse xenograft models that accept patient-derived xenografts and CD34+ cells were developed to better mimic tumor heterogeneity, the tumor microenvironment, and cross-talk between the tumor and stromal/immune cells. These features make them extremely valuable models for the evaluation of investigational cancer therapies, specifically new immunotherapies. Taken together, improvements in both the CRISPR/Cas9 system producing more valid mouse models and in the humanized mouse xenograft models resembling complex interactions between the tumor and its environment might represent one of the successful pathways to precise individualized cancer therapy, leading to improved cancer patient survival and quality of life.

Genetic Mouse Models of Lymphomas

Mouse Heterotopic Abdominal Heart Transplant Model

Mouse models of diffuse large B cell lymphoma

Genetically engineered mouse models in oncology research and cancer medicine

Genetically Engineered Mouse Models Support a Major Role of Immune Checkpoint-Dependent Immunosurveillance Escape in B-Cell Lymphomas

Mouse models of CLL: In vivo modeling of disease initiation, progression, and transformation

If you give a mouse a mutation: comparing the therapeutic utility of renowned mouse models of human cancers

Trials, Tribulations, and Trends in Tumor Modeling in Mice

Transgenic Mouse Models in Cancer Research

Mouse models in oncoimmunology

"Next top" mouse models advancing CTCL research

Mouse models for pre-clinical drug testing in leukemia

Genetically engineered mouse models of head and neck cancers

How Animal Models of Leukaemias Have Already Benefited Patients

[Research Progress in Transgenic Animal Models of Chronic Lymphocytic Leukemia -Review].

Models for mature T-cell lymphomas--a critical appraisal of experimental systems and their contribution to current T-cell tumorigenic concepts

How to Establish Acute Myeloid Leukemia Xenograft Models Using Immunodeficient Mice

Utilization of the Eμ-Myc mouse to model heterogeneity of therapeutic response

Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery

Humanized mouse models for immuno-oncology research

Mouse models of breast cancer in preclinical research